Sign up to save your podcasts
Or
Share CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.
View all episodes
By BiotechTV
4.3
77 ratings
The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.
More shows like BiotechTV - News
View all
WSJ What’s News
4,336 Listeners
The a16z Show
1,089 Listeners
The Meb Faber Show - Better Investing
948 Listeners
The Daily
111,841 Listeners
The Readout Loud
338 Listeners
The Intelligence from The Economist
2,544 Listeners
The Prof G Pod with Scott Galloway
5,365 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,141 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
35 Listeners
Biotech Hangout
21 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
468 Listeners
Prof G Markets
1,436 Listeners
The BioCentury Show
11 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners